ArticleAdvances in experimental medicine and biology2024
Economic Burden of Clostridioides difficile Infection in European Countries.
Article in Advances in experimental medicine and biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Cost-Effectiveness of Hospital-at-Home and Fecal Microbiota Transplantation in Treating Older Patients With Clostridioides difficile.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Trial
- Oral antibiotics prescribing patterns and associated diarrhea risk: Public health implications.Journal of public health research · 2026Article
- Characteristics, temporal trends and outcomes of Clostridioides difficile infection among hospitalized patients in Spain, 2016-2022.BMC infectious diseases · 2026Observational
- Increasing burden of Clostridioides difficile infection in Spain: nationwide trends in hospitalisations, 2016-2023.Antimicrobial resistance and infection control · 2026Observational
- Outpatient Parenteral Antimicrobial Therapy (OPAT) in Italy: A Scoping Review.Infectious diseases and therapy · 2026Review
- Article
- Epidemiology, recurrence, and mortality in patients withPathogens and global health · 2026Article
- Extracellular DNA filaments associated with surface polysaccharide II give Clostridioides difficile biofilm matrix a network-like structure.NPJ biofilms and microbiomes · 2025Article
- Whole-Genome Sequencing-Based Characterization ofMicroorganisms · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clostridioides difficile infection (CDI) remains a considerable challenge to healthcare systems worldwide. Although CDI represents a significant burden on healthcare systems in Europe, few studies have attempted to estimate the consumption of resources associated with CDI in Europe. The reported extra costs attributable to CDI vary widely according to the definitions, design, and methodologies used, making comparisons difficult to perform. In this chapter, the economic burden of healthcare facility-associated CDI in Europe will be assessed, as will other less explored areas such as the economic burden of recurrent CDI, community-acquired CDI, pediatric CDI, and CDI in outbreaks.
Indexed as
Identifiers
38175468What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.